Dialysis Complications Patient's Information Hotline Established:
Toll Free: 1-800-397-4046
Toll Free: 1-800-397-4046
If you or someone you love have suffered injuries after dialysis, contact our offices immediately for a free initial GranuFlo attorney lawsuit evaluation.
Use of the products are linked to causing metabolic alkalosis which can lead to:
The U.S. FDA, March 29, 2012 has issued a Class I recall for the popular dialysis treatment products. The Granuflo recall was issued due to a reasonable probability that these products cause serious side effects or even death.
Describe your case to an experienced attorney today, join our fight to hold the manufacturer responsible, you may be entitled to significant compensation.
The FDA issued a general safety warning, after the popular dialysis mixtures showed an increased risk of 400-600% for heart attacks or cardiac arrest following dialysis treatments in patients prescribed GranuFlo, according to Fresenius internal data (FDA).
Over 4,500 GranuFlo related heart attacks are suspected to have occurred in 2010, while over 260,000 Americans have had the products used during dialysis.
The recent findings indicate that people may not have been adequately alerted to the serious health risks associated and our GranuFlo lawyer is available to help with your questions regarding a potential lawsuit. If you suffered a heart attack, stroke or cardiac arrest following dialysis using GranuFlo or NaturaLyte, share what happened and get your legal consultation immediately.
Our law firm includes a former ICU nurse whose medical background can help provide you health related answers that you seek as well as the legal remedies that are available to you. If your loved one suffered a heart attack, stroke or died, and was taking the GranuFlo or NaturaLyte, we urge you to share what happened with our experienced GranuFlo lawsuit settlement attorneys and work with us to hold Fresenius responsible and claim what compensation you may have waiting for you.
Prior to the manufacturer recall, GranuFlo Dry Acid Concentrate and NaturaLyte were used to treat chronic renal (kidney) failure during hemodialysis with annual sales revenues estimated at $80 million or more. An internal memo from manufacturer Fresenius Medical Care North America, Nov. 4 2011, indicated the company knew of the significant heart attack risks during treatment. The company notified its own dialysis clinical network but the data was not shared with non Fresenius clinics.
Contact our personal injury law firm to learn about your GranuFlo lawsuit options, help us in the fight to hold Fresenius responsible, and you may be entitled to significant compensation for your injuries.